Resmetirom vs VK2809
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: Thyroid hormone receptor-beta · full MASH / NASH pipeline
Resmetirom · Rezdiffra
Marketed by Madrigal Pharmaceuticals
NCT03900429 · Phase 3 · active, not recruiting
MAESTRO-NASH was a randomized, double-blind, placebo-controlled Phase 3; the month-12 analysis included 888 patients with F2-F3 fibrosis. Both doses met both liver-biopsy endpoints. Biopsy histology is a surrogate that supported accelerated approval, not a clinical outcome, so the grade is moderate.
Next expected readout: December 2026 · NCT05500222 (registry estimate)
Reported efficacy
Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with Baseline (52 weeks); Month 54 Primary Objective: Time to experiencing an adjudicated Composite Clinical Outcome event (Final Primary Endpoint, at 54 months) (up to 54 months): Month-12 histology (n=888): MASH resolution without fibrosis worsening 26-27% (80 mg) and 24-36% (100 mg) vs 9-13% placebo; fibrosis improvement without MASH worsening 23% (80 mg) and 24-28% (100 mg) vs 13-15% placebo (ranges across the two pathologists); both endpoints statistically significant for both doses (REZDIFFRA label, Trial 1). (met)
Result source: NCT03900429
VK2809
Developed by Viking Therapeutics and partners
NCT04173065 · Phase 2 · completed
This randomized, quadruple-blind, placebo-controlled Phase 2b trial (n=248) in biopsy-confirmed NASH met its primary endpoint, an imaging marker of liver fat (MRI-PDFF) at 12 weeks, with reductions up to 51.7% versus placebo (p<0.0001). At 52 weeks the sponsor reports biopsy secondary endpoints: NASH resolution in 63% to 75% of VK2809 patients versus 29% on placebo, and fibrosis improvement in 44% to 57% versus 34% (significant in two of the dose arms only). The histology is a secondary endpoint reported by the sponsor; a registrational trial on a histology primary endpoint is still needed.
Caveat: the 12-week and 52-week figures are from company announcements, not from the trial registry or a peer-reviewed full paper. Treat them as the sponsor's own statement.
Reported efficacy
Liver Fat (12 weeks): Primary: liver fat reduction (MRI-PDFF) at Week 12, mean relative change -45.3% (2.5 mg QD), -36.8% (5 mg QOD), -51.7% (10 mg QOD), each p<0.0001 vs placebo. Secondary, 52-week biopsy: NASH resolution with no worsening of fibrosis 63% to 75% vs 29% placebo (p<0.05 each arm); >=1-stage fibrosis improvement with no worsening of NASH 44% to 57% vs 34% placebo (p<0.05 for the 5 mg and 10 mg QOD arms only). (met)
Result source: NCT04173065
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Resmetirom | VK2809 |
|---|---|---|
| MASH resolution without fibrosis worsening | 27.4% vs 14.7%+12.7 vs placeboNCT02912260 | —Not reported |
| Fibrosis stage, change | —Not posted · NCT04197479 | —Not reported |
| Liver fat (MRI-PDFF), change | -8.2% vs -2.9%−5.3 vs placeboNCT029122601 other result
| —Not reported |
| ALT, change | -15.4 vs 11−26.4 vs placeboNCT029122601 other result
| —Not reported |
MASH resolution without fibrosis worsening
- Resmetirom
- 27.4% vs 14.7%+12.7 vs placeboNCT02912260
- VK2809
- —Not reported
Fibrosis stage, change
- Resmetirom
- —Not posted · NCT04197479
- VK2809
- —Not reported
Liver fat (MRI-PDFF), change
- Resmetirom
- -8.2% vs -2.9%−5.3 vs placeboNCT02912260
1 other result
- -7% vs -2.7% NCT02912260
- VK2809
- —Not reported
ALT, change
- Resmetirom
- -15.4 vs 11−26.4 vs placeboNCT02912260
1 other result
- -8.2 vs -5.2 NCT02912260
- VK2809
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Resmetirom: 4 of 4 rows · VK2809: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Resmetirom | VK2809 |
|---|---|---|
| Dropout rate | —Extension Studya NCT02912260 · Phase 2 · registry result, not featured evidence show 2 more results11.9%MGL-3196 NCT02912260 · Phase 2 · registry result, not featured evidence —MGL-3196 Main Study NCT02912260 · Phase 2 · registry result, not featured evidence | — |
| Discontinued due to AEs | —Extension Studya NCT02912260 · Phase 2 · registry result, not featured evidence show 2 more results3.6%MGL-3196 NCT02912260 · Phase 2 · registry result, not featured evidence —MGL-3196 Main Study NCT02912260 · Phase 2 · registry result, not featured evidence | — |
| Serious AEs | 0%Extension Studya NCT02912260 · Phase 2 · registry result, not featured evidence show 2 more results—MGL-3196 NCT02912260 · Phase 2 · registry result, not featured evidence 6%MGL-3196 Main Study NCT02912260 · Phase 2 · registry result, not featured evidence | — |
| Most frequent reported AEs | a nasopharyngitis 9.7% (placebo 4.9%) abdominal discomfort 6.5% (placebo 0%) constipation 6.5% (placebo 0%) NCT02912260 · Phase 2 · registry result, not featured evidence show 1 more resultdiarrhoea 36.9% (placebo 9.8%) nausea 20.2% (placebo 4.9%) headache 13.1% (placebo 14.6%) NCT02912260 · Phase 2 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Resmetirom
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 3 further endpoints in the CSV export.
VK2809
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Resmetirom's landscape · VK2809's landscape